Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial.
- DOI
- 10.1007/s44402-026-00064-w
- Published
- 2026 Jul
- Container
- Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s44402-026-00064-w,
title = {Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01\% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial.},
author = {Zadnik K and Schulman E and Flitcroft I and Fogt JS and Blumenfeld LC and Fong TM and Lang E and Chandler SP and Hemmati HD and CHAMP trial Group Investigators},
year = {2026},
journal = {Ophthalmic \& physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)},
doi = {10.1007/s44402-026-00064-w},
url = {https://doi.org/10.1007/s44402-026-00064-w}
}RIS
TY - JOUR TI - Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial. AU - Zadnik K AU - Schulman E AU - Flitcroft I AU - Fogt JS AU - Blumenfeld LC AU - Fong TM AU - Lang E AU - Chandler SP AU - Hemmati HD AU - CHAMP trial Group Investigators PY - 2026 JO - Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) DO - 10.1007/s44402-026-00064-w UR - https://doi.org/10.1007/s44402-026-00064-w ER -
APA
K, Z., E, S., I, F., JS, F., LC, B., TM, F., E, L., SP, C., HD, H., & Investigators, C. T. G. (2026). Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial.. Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists). https://doi.org/10.1007/s44402-026-00064-w
Source records
- pubmed · retrieved 2026-09-25T17:48:20.669Z